Intermediate-term and long-term outcome of piggyback drainage: connecting glaucoma drainage device to a device in-situ for improved intraocular pressure control

2017 ◽  
Vol 45 (8) ◽  
pp. 803-811
Author(s):  
Edward Dervan ◽  
Edward Lee ◽  
Antonio Giubilato ◽  
Tina Khanam ◽  
Panayiotis Maghsoudlou ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Pressure Control ◽  
Glaucoma Drainage Device ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Drainage Device

Long-term outcome of low-cost glaucoma drainage device (Aurolab aqueous drainage implant) compared with Ahmed glaucoma valve

2019 ◽  
Vol 104 (4) ◽  
pp. 557-562 ◽  
Author(s):  
Surinder Singh Pandav ◽  
Natasha Gautam Seth ◽  
Faisal Thattaruthody ◽  
Manpreet Kaur ◽  
Madhuri Akella ◽  
...  
Keyword(s):  
Postoperative Period ◽  
Low Cost ◽  
Glaucoma Drainage Device ◽  
Ahmed Glaucoma Valve ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Surgical Interventions ◽  
Drainage Device ◽  
Late Postoperative Period

PurposeTo compare the long-term outcome of Aurolab aqueous drainage device (AADI) and Ahmed glaucoma valve (AGV).MethodRetrospective analysis of patients with refractory glaucoma who underwent AGV (AGV-FP7) and AADI (AADI Model 350) implantation. The outcome measures were intraocular pressure (IOP), requirement of antiglaucoma medications (AGMs) and re-surgery for IOP control. The postoperative complications were classified as early (≤3 months), intermediate (>3 months to ≤1 year) or late (>1 year).Results173 patients (189 eyes) underwent AGV implantation (AGV Group) while 201 patients (206 eyes) underwent AADI implantation (AADI group). The IOP in AADI group was significantly lower than AGV group at all time points till 2 years and comparable at 3 years. AADI group had significantly higher number of AGM in preoperative period and significantly lower number in postoperative period till 3 years compared with AGV group. AADI group had more hypotony-related complications but statistically insignificant (p = 0.07). The surgical interventions were significantly higher in AGV (n = 18) compared with AADI group (n = 5) in late postoperative period (p = 0.01). At 3 years, overall success was seen in 58.18% in AGV and 73.08% in AADI group (p = 0.15). Complete success was seen in 7.27% patients in AGV and 25.00% patients in AADI group (p = 0.02).ConclusionBoth AADI and AGV implant had comparable mean IOP at 3 years with lesser requirement of AGM in the AADI group. Both procedures appear to be safe with slight preponderance of hypotony-related complications in AADI group.

Long-term outcome of bacilles Calmette-Guerin perfusion therapy for upper urinary tract urothelial carcinoma in situ.

2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 265-265
Author(s):  
Takahiro Yoneyama ◽  
Naoki Sugiyama ◽  
Yuuichirou Suzuki ◽  
Akiko Okamoto ◽  
Hayato Yamamoto ◽  
...  
Keyword(s):  
Urinary Tract ◽  
Side Effects ◽  
Urothelial Carcinoma ◽  
Carcinoma In Situ ◽  
Upper Urinary Tract ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Urinary Tract Urothelial Carcinoma

265 Background: Bacillus Calmette-Guerin (BCG) therapy has already been established as a treatment for muscle noninvasive bladder cancer. Although there are several reports indicating the effectiveness of BCG perfusion therapy for the upper urinary tract urothelial carcinoma in situ (CIS), it is not well established yet. We conducted a retrospective study to assess the long-term outcome of BCG perfusion therapy for the upper urinary tract CIS. Methods: Twenty-six subjects (20 male, 6 female) who received BCG perfusion therapy for the upper urinary tract CIS from December 1997 to December 2011 were enrolled. Ten subjects had the entire urinary tract CIS, seven had bilateral, nine had unilateral CIS of the urinary tract. The average period of observation was 52.6 months (ranging from 5 to 156 months), and the average subject age was 73.6 years (ranging from 56 to 90 years). We used a double-J catheter for 17 cases, a transvesical single-J catheter whose curl was positions in an upper calyx for eight cases, and a straight ureteral catheter inserted for ureterocutaneostomy for one case. We used 80 mg of BCG for the first five cases, 40 mg for the late twenty-one cases. Urine cytology was performed to assess the treatment validity. Results: Of the 26 cases, the treatment protocol was completed in 21 cases. Urine cytology tests became negative in 22 of the 26 subjects (84.6%) who underwent upper urinary tract perfusion. Among these 22 subjects who had negative tests, five subjects had a recurrence in their upper urinary tracts. Side effects were observed in 25 subjects (96.5%), and the most common side effect was bladder irritation. Localized renal tuberculosis which was successfully treated with conservative therapy was seen in two cases. Conclusions: BCG perfusion therapy for the upper urinary tract CIS is active. However, severe side effects are possible, and careful observation is essential while using this therapy.

Sign in / Sign up

Export Citation Format

Share Document